Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA urges “regular order” for health reform

Executive Summary

The Pharmaceutical Research and Manufacturers of America is urging Congress to avoid passing health care reform as part of the budget reconciliation process. Taking up reform through reconciliation would allow the Senate to clear it with 51 votes, as opposed to the filibuster-breaking 60 votes. Both chambers passed the budget blueprint on April 2; the Senate version does not allow for health care reform and other measures to be taken up in reconciliation, while the House version does. PhRMA's statement said: "To help keep the bipartisan spirit alive, PhRMA urges the budget conferees to pursue a process of regular order for health care reform so that members on both sides of the aisle can continue to have an open and constructive debate about important health care reform policy changes. In addition, we believe that pursuing health reform through reconciliation would preclude Congress from considering a number of critical reforms that fall outside the scope of a reconciliation bill.

You may also be interested in...

Does Polivy Provide A Cure For DLBCL? Too Early To Say, Argue NICE Experts

Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.

Back With A Bang: ‘Brexit Bill’ For UK’s Medical Devices Due For 2nd Reading On 2 March

Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.

EU Funding For COVID-19 Drug & Diagnostic Research

Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts